Immune-Enhancing Effect of Heat-Treated Levilactobacillus brevis KU15159 in RAW 264.7 Cells.
Immune-enhancing
Levilactobacillus brevis
MAPK signaling pathway
Probiotics
RAW 264.7 cell
Journal
Probiotics and antimicrobial proteins
ISSN: 1867-1314
Titre abrégé: Probiotics Antimicrob Proteins
Pays: United States
ID NLM: 101484100
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
accepted:
23
09
2022
pubmed:
1
10
2022
medline:
18
1
2023
entrez:
30
9
2022
Statut:
ppublish
Résumé
Probiotics are alive microbes that present beneficial to the human's health. They influence immune responses through stimulating antibody production, activating T cells, and altering cytokine expression. The probiotic characteristics of Levilactobacillus brevis KU15159 were evaluated on the tolerance and adherence to gastrointestinal conditions. L. brevis KU15159 was safe in a view of producing various useful enzymes and antibiotic sensitivity. Heat-treated L. brevis KU15159 increased production of nitric oxide (NO) and phagocytic activity in RAW 264.7 cells. In addition, heat-treated L. brevis KU15159 upregulated the expression of inducible nitric oxide synthase (iNOS) and proinflammatory cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, at protein as well as mRNA levels. In addition, the mitogen-activated protein kinase (MAPK) pathway, which regulates the immune system, was activated by heat-treated L. brevis KU15159. Therefore, L. brevis KU15159 exhibited an immune-enhancing effect by the MAPK pathway in macrophage.
Identifiants
pubmed: 36178579
doi: 10.1007/s12602-022-09996-4
pii: 10.1007/s12602-022-09996-4
pmc: PMC9523639
doi:
Substances chimiques
Cytokines
0
Mitogen-Activated Protein Kinases
EC 2.7.11.24
Tumor Necrosis Factor-alpha
0
Nitric Oxide Synthase Type II
EC 1.14.13.39
Nitric Oxide
31C4KY9ESH
Lipopolysaccharides
0
NF-kappa B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
175-184Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Int Immunopharmacol. 2018 Jul;60:141-151
pubmed: 29730557
J Microbiol Biotechnol. 2019 Aug 28;29(8):1248-1254
pubmed: 31216788
Microb Pathog. 2020 Oct;147:104430
pubmed: 32758520
Int J Mol Sci. 2022 Apr 07;23(8):
pubmed: 35456891
Toxicol In Vitro. 2020 Mar;63:104745
pubmed: 31830504
J Cell Physiol. 2019 Aug;234(10):17127-17143
pubmed: 30912128
Pharm Biol. 2017 Dec;55(1):2095-2101
pubmed: 28832232
Food Sci Biotechnol. 2018 Sep 27;28(2):491-499
pubmed: 30956861
J Microbiol Biotechnol. 2020 Apr 28;30(4):591-598
pubmed: 32238771
Poult Sci. 2017 Sep 1;96(11):3872-3878
pubmed: 29050435
Food Sci Biotechnol. 2021 Jan 6;30(2):257-265
pubmed: 33732516
Braz J Microbiol. 2017 Jul - Sep;48(3):576-586
pubmed: 28552660
Front Immunol. 2014 Oct 07;5:491
pubmed: 25339958
Pharm Res. 2015 Mar;32(3):876-97
pubmed: 25208875
Food Sci Biotechnol. 2016 Aug 31;25(4):1129-1133
pubmed: 30263385
Int J Environ Res Public Health. 2021 Dec 21;19(1):
pubmed: 35010297
Proc Natl Acad Sci U S A. 2018 Jun 5;115(23):5839-5848
pubmed: 29802228
Nutrients. 2021 Apr 01;13(4):
pubmed: 33915854
Sci Total Environ. 2021 Apr 15;765:142681
pubmed: 33071139
J Microbiol Biotechnol. 2019 May 28;29(5):704-712
pubmed: 30982316
Food Sci Biotechnol. 2020 Nov 23;30(1):97-106
pubmed: 33552621
Int J Mol Sci. 2018 Nov 29;19(12):
pubmed: 30501075
Food Sci Biotechnol. 2017 Nov 14;27(1):123-129
pubmed: 30263732
Antioxidants (Basel). 2022 Jan 28;11(2):
pubmed: 35204151
Food Chem. 2021 Dec 15;365:130501
pubmed: 34247050
Carbohydr Polym. 2018 Sep 15;196:445-456
pubmed: 29891317
J Dairy Sci. 2022 Apr;105(4):2750-2770
pubmed: 35221064
BMC Microbiol. 2018 Dec 19;18(1):219
pubmed: 30567551
Int J Biol Macromol. 2019 Apr 1;126:960-968
pubmed: 30590152
Int J Mol Sci. 2022 Jan 27;23(3):
pubmed: 35163375
Biomed Pharmacother. 2022 Aug;152:113258
pubmed: 35709651
J Food Biochem. 2021 Apr;45(4):e13631
pubmed: 33528053
Biomed Res Int. 2018 Oct 23;2018:8063647
pubmed: 30426014